Ph3b Evolocumab in HIV Patients
Research payments
$524,338
Through program year 2021, $524,338 in research payments was reported against Ph3b Evolocumab in HIV Patients, across 115 payments, paid by Amgen Inc..
- Paid by
- Amgen Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2021 | Research | $4,296 | 5 |
| 2020 | Research | $76,795 | 36 |
| 2019 | Research | $443,246 | 74 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Robert Rosenson New York, NY Named on 9 payments
- Joseph Sacco Albany, NY Named on 8 payments
- Jamie Morano Tampa, FL Named on 8 payments
- Deborah Goldstein Washington, DC Named on 7 payments
- Kara Chew Los Angeles, CA Named on 7 payments
- Carl Fichtenbaum Cincinnati, OH Named on 6 payments
- David Parenti Washington, DC Named on 6 payments
- Princy Kumar Washington, DC Named on 6 payments
- Jason Baker Minneapolis, MN Named on 6 payments
- Gerald Pierone Vero Beach, FL Named on 6 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.